Serveur d'exploration sur la musique en Sarre

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Danger signals and skin sensitization

Identifieur interne : 000E56 ( Istex/Corpus ); précédent : 000E55; suivant : 000E57

Danger signals and skin sensitization

Auteurs : I. Kimber ; M. Cumberbatch ; R. J. Dearman ; C. E. M. Griffiths

Source :

RBID : ISTEX:8D83CB0E5B4E7E46ABB16B639A65C513623A8340

English descriptors


Url:
DOI: 10.1046/j.1365-2133.2002.48776.x

Links to Exploration step

ISTEX:8D83CB0E5B4E7E46ABB16B639A65C513623A8340

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Danger signals and skin sensitization</title>
<author>
<name sortKey="Kimber, I" sort="Kimber, I" uniqKey="Kimber I" first="I." last="Kimber">I. Kimber</name>
<affiliation>
<mods:affiliation>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Cumberbatch, M" sort="Cumberbatch, M" uniqKey="Cumberbatch M" first="M." last="Cumberbatch">M. Cumberbatch</name>
<affiliation>
<mods:affiliation>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Dearman, R J" sort="Dearman, R J" uniqKey="Dearman R" first="R. J." last="Dearman">R. J. Dearman</name>
<affiliation>
<mods:affiliation>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Griffiths, C E M" sort="Griffiths, C E M" uniqKey="Griffiths C" first="C. E. M." last="Griffiths">C. E. M. Griffiths</name>
<affiliation>
<mods:affiliation>The Dermatology Centre, University of Manchester, Manchester, U.K. Correspondence: I. Kimber E‐mail: ian.kimber@syngenta.com</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8D83CB0E5B4E7E46ABB16B639A65C513623A8340</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1046/j.1365-2133.2002.48776.x</idno>
<idno type="url">https://api.istex.fr/document/8D83CB0E5B4E7E46ABB16B639A65C513623A8340/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000E56</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E56</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Danger signals and skin sensitization</title>
<author>
<name sortKey="Kimber, I" sort="Kimber, I" uniqKey="Kimber I" first="I." last="Kimber">I. Kimber</name>
<affiliation>
<mods:affiliation>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Cumberbatch, M" sort="Cumberbatch, M" uniqKey="Cumberbatch M" first="M." last="Cumberbatch">M. Cumberbatch</name>
<affiliation>
<mods:affiliation>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Dearman, R J" sort="Dearman, R J" uniqKey="Dearman R" first="R. J." last="Dearman">R. J. Dearman</name>
<affiliation>
<mods:affiliation>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Griffiths, C E M" sort="Griffiths, C E M" uniqKey="Griffiths C" first="C. E. M." last="Griffiths">C. E. M. Griffiths</name>
<affiliation>
<mods:affiliation>The Dermatology Centre, University of Manchester, Manchester, U.K. Correspondence: I. Kimber E‐mail: ian.kimber@syngenta.com</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">British Journal of Dermatology</title>
<idno type="ISSN">0007-0963</idno>
<idno type="eISSN">1365-2133</idno>
<imprint>
<publisher>Blackwell Science Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2002-09">2002-09</date>
<biblScope unit="volume">147</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="613">613</biblScope>
<biblScope unit="page" to="613">613</biblScope>
</imprint>
<idno type="ISSN">0007-0963</idno>
</series>
<idno type="istex">8D83CB0E5B4E7E46ABB16B639A65C513623A8340</idno>
<idno type="DOI">10.1046/j.1365-2133.2002.48776.x</idno>
<idno type="ArticleID">BJD4877_6</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0007-0963</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="Teeft" xml:lang="en">
<term>Acad dermatol</term>
<term>Adaptive immunity</term>
<term>Allergen</term>
<term>Allergic contact dermatitis</term>
<term>Angiotensin</term>
<term>Apoptosis</term>
<term>Apoptotic cells</term>
<term>Arch dermatol</term>
<term>Asthmatic patients</term>
<term>Atrophoderma</term>
<term>Autosomal recessive inheritance</term>
<term>Basal</term>
<term>Basal cell carcinoma</term>
<term>Basal cell carcinomas</term>
<term>Basiliximab</term>
<term>Biopsy</term>
<term>Blood transfusion</term>
<term>Bone marrow</term>
<term>Bone pain</term>
<term>Book deals</term>
<term>Book reviews</term>
<term>Bowel</term>
<term>Bowel disease</term>
<term>British association</term>
<term>British journal</term>
<term>British skin foundation</term>
<term>Bystander</term>
<term>Candesartan cilexetil</term>
<term>Carcinoma</term>
<term>Cardiac abnormalities</term>
<term>Case report</term>
<term>Cell death</term>
<term>Cell markers</term>
<term>Cell precursor</term>
<term>Central role</term>
<term>Chain gene</term>
<term>Chemical allergen</term>
<term>Chemical allergens</term>
<term>Chronic trauma</term>
<term>Clin</term>
<term>Clinical features</term>
<term>Clinical investigation</term>
<term>Clinicopathologic study</term>
<term>Commonest skin cancer</term>
<term>Congenital</term>
<term>Congenital ichthyosis</term>
<term>Contact dermatitis</term>
<term>Correspondence figure</term>
<term>Creatinine clearance</term>
<term>Crmo</term>
<term>Cutaneous</term>
<term>Cutaneous lesions</term>
<term>Cyclosporin</term>
<term>Cytokine</term>
<term>Cytokine signals</term>
<term>Cytotoxic molecules</term>
<term>Danger hypothesis</term>
<term>Danger model</term>
<term>Danger signals</term>
<term>Dermatitis</term>
<term>Dermatol</term>
<term>Dermatol surg oncol</term>
<term>Dermatologist</term>
<term>Dermatology</term>
<term>Differential diagnosis</term>
<term>Docetaxel</term>
<term>Dramatic response</term>
<term>Drug compatibility</term>
<term>Drug intake</term>
<term>Drug reaction</term>
<term>Drug reactions</term>
<term>Eosin staining</term>
<term>Epidermal</term>
<term>Erosive</term>
<term>Erosive vulvovaginal lichen planus</term>
<term>Extensor surfaces</term>
<term>Family history</term>
<term>Fatal hyalohyphomycosis</term>
<term>Flow cytometric analysis</term>
<term>Focal hypogranulosis</term>
<term>Follicular</term>
<term>Follicular atrophoderma</term>
<term>Foreign antigen</term>
<term>Full blood cell count</term>
<term>Functional subpopulations</term>
<term>Fungal melanonychia</term>
<term>Fusarium</term>
<term>Fusarium onychomycosis</term>
<term>Fusarium oxysporum</term>
<term>Fusarium solani</term>
<term>Genodermatosis</term>
<term>Gold particles</term>
<term>Granulocytic</term>
<term>Granulocytic sarcoma</term>
<term>Granulocytic sarcomas</term>
<term>Great toenails</term>
<term>Haematopoietic neoplasms</term>
<term>Happle syndrome</term>
<term>Host resistance</term>
<term>Hypotrichosis</term>
<term>Ichthyosis</term>
<term>Ichthyosis vulgaris</term>
<term>Ichthyotic skin</term>
<term>Imiquimod</term>
<term>Immune</term>
<term>Immune response</term>
<term>Immune system</term>
<term>Immunohistochemical staining</term>
<term>Immunol</term>
<term>Important role</term>
<term>Inheritance pattern</term>
<term>Initial presentation</term>
<term>Intralesional corticosteroids</term>
<term>Introductory section</term>
<term>Irregular diameter</term>
<term>Keratinocytes</term>
<term>Lactophenol cotton</term>
<term>Langerhans</term>
<term>Langerhans cell migration</term>
<term>Langerhans cells</term>
<term>Large part</term>
<term>Lesion</term>
<term>Leukaemia</term>
<term>Leukaemia cutis</term>
<term>Lichen</term>
<term>Local wound therapy</term>
<term>Localized</term>
<term>Lower extremities</term>
<term>Lower right</term>
<term>Lymph</term>
<term>Lymph nodes</term>
<term>Lymphoma</term>
<term>Major improvement</term>
<term>Malignant</term>
<term>Malignant melanoma</term>
<term>Mechanical injury</term>
<term>Melanoma</term>
<term>Metastasis</term>
<term>Metastatic</term>
<term>Metastatic skin area</term>
<term>Monoclonal antibody</term>
<term>Montelukast</term>
<term>Montelukast therapy</term>
<term>Mouse skin</term>
<term>Multifocal</term>
<term>Multifocal osteomyelitis</term>
<term>Myeloid</term>
<term>Myeloid cell markers</term>
<term>Myeloid precursor</term>
<term>Nail</term>
<term>Nail unit</term>
<term>Nailfold capillaroscopy</term>
<term>Natural killer</term>
<term>Ndings</term>
<term>Neural cell adhesion molecule</term>
<term>Nimesulide</term>
<term>Node</term>
<term>Normal range</term>
<term>Nuclear accumulation</term>
<term>Onychomycosis</term>
<term>Oral prednisolone</term>
<term>Oral prednisone</term>
<term>Oral sulphasalazine</term>
<term>Oral terbinafine</term>
<term>Osteomyelitis</term>
<term>Other cytokines</term>
<term>Other signals</term>
<term>Paclitaxel</term>
<term>Palmoplantar</term>
<term>Palmoplantar keratoderma</term>
<term>Palmoplantar pustular psoriasis</term>
<term>Patch testing</term>
<term>Pediatr dermatol</term>
<term>Pigmentation disorders</term>
<term>Planus</term>
<term>Platelet</term>
<term>Platelet count</term>
<term>Positive staining</term>
<term>Positive tunel staining</term>
<term>Precursor</term>
<term>Professional radiodermatitis</term>
<term>Psoriasis</term>
<term>Pustular</term>
<term>Pustular psoriasis</term>
<term>Pustule</term>
<term>Pustuloderma</term>
<term>Pyoderma gangrenosum</term>
<term>Rare case</term>
<term>Receptor</term>
<term>References figure</term>
<term>Regional lymph nodes</term>
<term>Santa cruz biotechnology</term>
<term>Sarcoma</term>
<term>Sartan</term>
<term>Sartan treatment</term>
<term>Sartans</term>
<term>Scalp hair</term>
<term>Second report</term>
<term>Sensitization</term>
<term>Severe thrombocytopenia</term>
<term>Skin biopsies</term>
<term>Skin biopsy</term>
<term>Skin disorders</term>
<term>Skin involvement</term>
<term>Skin irritation</term>
<term>Skin lesions</term>
<term>Skin metastases</term>
<term>Skin sensitization</term>
<term>Solani</term>
<term>Successful treatment</term>
<term>Syndrome</term>
<term>Systemic vasculitis</term>
<term>Tacrolimus</term>
<term>Taipei</term>
<term>Teledermatology</term>
<term>Teledermatology service</term>
<term>Terminal deoxynucleotidyl deoxyuridine triphosphate nick</term>
<term>Therapeutic class</term>
<term>Thrombocytopenia</term>
<term>Time course</term>
<term>Tissue remodelling</term>
<term>Tissue staining</term>
<term>Toenail</term>
<term>Topical</term>
<term>Topical application</term>
<term>Topical cyclosporin</term>
<term>Topical imiquimod</term>
<term>Topical imiquimod treatment</term>
<term>Topical tacrolimus</term>
<term>Topical treatment</term>
<term>Toxic pustuloderma</term>
<term>Transient myalgia</term>
<term>Trauma</term>
<term>Tumour</term>
<term>Tumour cells</term>
<term>Tumour necrosis</term>
<term>Tunel</term>
<term>Tunel staining</term>
<term>Ultrasound imaging</term>
<term>University hospital</term>
<term>Upper right</term>
<term>Viral infection</term>
<term>Vulval</term>
<term>Vulval mucosa</term>
<term>Western blot analysis</term>
<term>Wire brush</term>
<term>Woolly</term>
<term>Woolly hair</term>
<term>Wooly hair</term>
<term>Wound edge</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<istex>
<corpusName>wiley</corpusName>
<keywords>
<teeft>
<json:string>dermatology</json:string>
<json:string>dermatol</json:string>
<json:string>dermatologist</json:string>
<json:string>psoriasis</json:string>
<json:string>tumour</json:string>
<json:string>cutaneous</json:string>
<json:string>british journal</json:string>
<json:string>imiquimod</json:string>
<json:string>british association</json:string>
<json:string>ichthyosis</json:string>
<json:string>tacrolimus</json:string>
<json:string>teledermatology</json:string>
<json:string>apoptosis</json:string>
<json:string>erosive</json:string>
<json:string>fusarium</json:string>
<json:string>platelet</json:string>
<json:string>woolly hair</json:string>
<json:string>thrombocytopenia</json:string>
<json:string>cytokine</json:string>
<json:string>atrophoderma</json:string>
<json:string>nimesulide</json:string>
<json:string>follicular atrophoderma</json:string>
<json:string>receptor</json:string>
<json:string>immune</json:string>
<json:string>multifocal</json:string>
<json:string>basiliximab</json:string>
<json:string>osteomyelitis</json:string>
<json:string>node</json:string>
<json:string>basal</json:string>
<json:string>montelukast</json:string>
<json:string>platelet count</json:string>
<json:string>hypotrichosis</json:string>
<json:string>sarcoma</json:string>
<json:string>crmo</json:string>
<json:string>metastasis</json:string>
<json:string>cyclosporin</json:string>
<json:string>ndings</json:string>
<json:string>immunol</json:string>
<json:string>pustular</json:string>
<json:string>onychomycosis</json:string>
<json:string>sensitization</json:string>
<json:string>melanoma</json:string>
<json:string>dermatitis</json:string>
<json:string>vulval</json:string>
<json:string>syndrome</json:string>
<json:string>lichen</json:string>
<json:string>angiotensin</json:string>
<json:string>malignant</json:string>
<json:string>topical tacrolimus</json:string>
<json:string>multifocal osteomyelitis</json:string>
<json:string>paclitaxel</json:string>
<json:string>clin</json:string>
<json:string>metastatic</json:string>
<json:string>bowel</json:string>
<json:string>epidermal</json:string>
<json:string>danger signals</json:string>
<json:string>sartans</json:string>
<json:string>allergen</json:string>
<json:string>leukaemia</json:string>
<json:string>precursor</json:string>
<json:string>planus</json:string>
<json:string>pustuloderma</json:string>
<json:string>langerhans</json:string>
<json:string>topical treatment</json:string>
<json:string>docetaxel</json:string>
<json:string>granulocytic sarcoma</json:string>
<json:string>arch dermatol</json:string>
<json:string>follicular</json:string>
<json:string>lymphoma</json:string>
<json:string>genodermatosis</json:string>
<json:string>palmoplantar</json:string>
<json:string>mechanical injury</json:string>
<json:string>sartan</json:string>
<json:string>keratinocytes</json:string>
<json:string>solani</json:string>
<json:string>toenail</json:string>
<json:string>pustule</json:string>
<json:string>tunel</json:string>
<json:string>skin sensitization</json:string>
<json:string>bystander</json:string>
<json:string>lesion</json:string>
<json:string>carcinoma</json:string>
<json:string>acad dermatol</json:string>
<json:string>myeloid</json:string>
<json:string>topical</json:string>
<json:string>granulocytic</json:string>
<json:string>sartan treatment</json:string>
<json:string>great toenails</json:string>
<json:string>patch testing</json:string>
<json:string>topical imiquimod</json:string>
<json:string>pyoderma gangrenosum</json:string>
<json:string>malignant melanoma</json:string>
<json:string>contact dermatitis</json:string>
<json:string>skin lesions</json:string>
<json:string>basal cell carcinoma</json:string>
<json:string>immune system</json:string>
<json:string>drug reaction</json:string>
<json:string>eosin staining</json:string>
<json:string>lymph nodes</json:string>
<json:string>palmoplantar keratoderma</json:string>
<json:string>congenital ichthyosis</json:string>
<json:string>skin biopsy</json:string>
<json:string>topical imiquimod treatment</json:string>
<json:string>cutaneous lesions</json:string>
<json:string>university hospital</json:string>
<json:string>danger hypothesis</json:string>
<json:string>successful treatment</json:string>
<json:string>allergic contact dermatitis</json:string>
<json:string>santa cruz biotechnology</json:string>
<json:string>biopsy</json:string>
<json:string>lymph</json:string>
<json:string>congenital</json:string>
<json:string>trauma</json:string>
<json:string>localized</json:string>
<json:string>taipei</json:string>
<json:string>chemical allergens</json:string>
<json:string>british skin foundation</json:string>
<json:string>functional subpopulations</json:string>
<json:string>tumour necrosis</json:string>
<json:string>langerhans cells</json:string>
<json:string>pediatr dermatol</json:string>
<json:string>wire brush</json:string>
<json:string>clinicopathologic study</json:string>
<json:string>teledermatology service</json:string>
<json:string>pustular psoriasis</json:string>
<json:string>bowel disease</json:string>
<json:string>creatinine clearance</json:string>
<json:string>inheritance pattern</json:string>
<json:string>topical application</json:string>
<json:string>positive staining</json:string>
<json:string>skin metastases</json:string>
<json:string>tumour cells</json:string>
<json:string>ichthyotic skin</json:string>
<json:string>toxic pustuloderma</json:string>
<json:string>family history</json:string>
<json:string>ichthyosis vulgaris</json:string>
<json:string>second report</json:string>
<json:string>nail unit</json:string>
<json:string>oral prednisolone</json:string>
<json:string>immune response</json:string>
<json:string>candesartan cilexetil</json:string>
<json:string>woolly</json:string>
<json:string>granulocytic sarcomas</json:string>
<json:string>regional lymph nodes</json:string>
<json:string>host resistance</json:string>
<json:string>foreign antigen</json:string>
<json:string>fusarium oxysporum</json:string>
<json:string>skin irritation</json:string>
<json:string>danger model</json:string>
<json:string>other cytokines</json:string>
<json:string>chemical allergen</json:string>
<json:string>cytotoxic molecules</json:string>
<json:string>viral infection</json:string>
<json:string>large part</json:string>
<json:string>fusarium onychomycosis</json:string>
<json:string>other signals</json:string>
<json:string>cytokine signals</json:string>
<json:string>references figure</json:string>
<json:string>myeloid precursor</json:string>
<json:string>langerhans cell migration</json:string>
<json:string>bone marrow</json:string>
<json:string>lactophenol cotton</json:string>
<json:string>irregular diameter</json:string>
<json:string>important role</json:string>
<json:string>apoptotic cells</json:string>
<json:string>tissue remodelling</json:string>
<json:string>cell precursor</json:string>
<json:string>local wound therapy</json:string>
<json:string>tissue staining</json:string>
<json:string>terminal deoxynucleotidyl deoxyuridine triphosphate nick</json:string>
<json:string>fungal melanonychia</json:string>
<json:string>rare case</json:string>
<json:string>western blot analysis</json:string>
<json:string>wound edge</json:string>
<json:string>tunel staining</json:string>
<json:string>nuclear accumulation</json:string>
<json:string>gold particles</json:string>
<json:string>positive tunel staining</json:string>
<json:string>mouse skin</json:string>
<json:string>intralesional corticosteroids</json:string>
<json:string>fatal hyalohyphomycosis</json:string>
<json:string>oral sulphasalazine</json:string>
<json:string>fusarium solani</json:string>
<json:string>initial presentation</json:string>
<json:string>therapeutic class</json:string>
<json:string>myeloid cell markers</json:string>
<json:string>transient myalgia</json:string>
<json:string>montelukast therapy</json:string>
<json:string>skin biopsies</json:string>
<json:string>asthmatic patients</json:string>
<json:string>skin involvement</json:string>
<json:string>lower extremities</json:string>
<json:string>systemic vasculitis</json:string>
<json:string>palmoplantar pustular psoriasis</json:string>
<json:string>dramatic response</json:string>
<json:string>wooly hair</json:string>
<json:string>nailfold capillaroscopy</json:string>
<json:string>normal range</json:string>
<json:string>clinical features</json:string>
<json:string>autosomal recessive inheritance</json:string>
<json:string>cardiac abnormalities</json:string>
<json:string>basal cell carcinomas</json:string>
<json:string>case report</json:string>
<json:string>leukaemia cutis</json:string>
<json:string>flow cytometric analysis</json:string>
<json:string>upper right</json:string>
<json:string>ultrasound imaging</json:string>
<json:string>metastatic skin area</json:string>
<json:string>extensor surfaces</json:string>
<json:string>monoclonal antibody</json:string>
<json:string>correspondence figure</json:string>
<json:string>happle syndrome</json:string>
<json:string>cell markers</json:string>
<json:string>differential diagnosis</json:string>
<json:string>focal hypogranulosis</json:string>
<json:string>clinical investigation</json:string>
<json:string>chain gene</json:string>
<json:string>immunohistochemical staining</json:string>
<json:string>drug reactions</json:string>
<json:string>drug intake</json:string>
<json:string>haematopoietic neoplasms</json:string>
<json:string>erosive vulvovaginal lichen planus</json:string>
<json:string>scalp hair</json:string>
<json:string>adaptive immunity</json:string>
<json:string>skin disorders</json:string>
<json:string>major improvement</json:string>
<json:string>vulval mucosa</json:string>
<json:string>topical cyclosporin</json:string>
<json:string>drug compatibility</json:string>
<json:string>natural killer</json:string>
<json:string>severe thrombocytopenia</json:string>
<json:string>full blood cell count</json:string>
<json:string>blood transfusion</json:string>
<json:string>lower right</json:string>
<json:string>central role</json:string>
<json:string>time course</json:string>
<json:string>neural cell adhesion molecule</json:string>
<json:string>oral terbinafine</json:string>
<json:string>professional radiodermatitis</json:string>
<json:string>pigmentation disorders</json:string>
<json:string>commonest skin cancer</json:string>
<json:string>chronic trauma</json:string>
<json:string>book reviews</json:string>
<json:string>oral prednisone</json:string>
<json:string>dermatol surg oncol</json:string>
<json:string>bone pain</json:string>
<json:string>introductory section</json:string>
<json:string>book deals</json:string>
<json:string>cell death</json:string>
<json:string>nail</json:string>
</teeft>
</keywords>
<author>
<json:item>
<name>I. Kimber</name>
<affiliations>
<json:string>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</json:string>
</affiliations>
</json:item>
<json:item>
<name>M. Cumberbatch</name>
<affiliations>
<json:string>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</json:string>
</affiliations>
</json:item>
<json:item>
<name>R.J. Dearman</name>
<affiliations>
<json:string>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</json:string>
</affiliations>
</json:item>
<json:item>
<name>C.E.M. Griffiths</name>
<affiliations>
<json:string>The Dermatology Centre, University of Manchester, Manchester, U.K. Correspondence: I. Kimber E‐mail: ian.kimber@syngenta.com</json:string>
</affiliations>
</json:item>
</author>
<articleId>
<json:string>BJD4877_6</json:string>
</articleId>
<language>
<json:string>eng</json:string>
</language>
<originalGenre>
<json:string>letter</json:string>
</originalGenre>
<qualityIndicators>
<score>5.012</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>595 x 782 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractCharCount>0</abstractCharCount>
<pdfWordCount>15451</pdfWordCount>
<pdfCharCount>100973</pdfCharCount>
<pdfPageCount>28</pdfPageCount>
<abstractWordCount>1</abstractWordCount>
</qualityIndicators>
<title>Danger signals and skin sensitization</title>
<genre>
<json:string>review-article</json:string>
</genre>
<host>
<title>British Journal of Dermatology</title>
<language>
<json:string>unknown</json:string>
</language>
<doi>
<json:string>10.1111/(ISSN)1365-2133</json:string>
</doi>
<issn>
<json:string>0007-0963</json:string>
</issn>
<eissn>
<json:string>1365-2133</json:string>
</eissn>
<publisherId>
<json:string>BJD</json:string>
</publisherId>
<volume>147</volume>
<issue>3</issue>
<pages>
<first>613</first>
<last>613</last>
<total>2</total>
</pages>
<genre>
<json:string>journal</json:string>
</genre>
</host>
<categories>
<wos>
<json:string>science</json:string>
<json:string>dermatology</json:string>
</wos>
<scienceMetrix>
<json:string>health sciences</json:string>
<json:string>clinical medicine</json:string>
<json:string>dermatology & venereal diseases</json:string>
</scienceMetrix>
</categories>
<publicationDate>2002</publicationDate>
<copyrightDate>2002</copyrightDate>
<doi>
<json:string>10.1046/j.1365-2133.2002.48776.x</json:string>
</doi>
<id>8D83CB0E5B4E7E46ABB16B639A65C513623A8340</id>
<score>1</score>
<fulltext>
<json:item>
<extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/8D83CB0E5B4E7E46ABB16B639A65C513623A8340/fulltext/pdf</uri>
</json:item>
<json:item>
<extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/8D83CB0E5B4E7E46ABB16B639A65C513623A8340/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/8D83CB0E5B4E7E46ABB16B639A65C513623A8340/fulltext/tei">
<teiHeader>
<fileDesc>
<titleStmt>
<title level="a" type="main" xml:lang="en">Danger signals and skin sensitization</title>
</titleStmt>
<publicationStmt>
<authority>ISTEX</authority>
<publisher>Blackwell Science Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<availability>
<p>WILEY</p>
</availability>
<date>2002</date>
</publicationStmt>
<sourceDesc>
<biblStruct type="inbook">
<analytic>
<title level="a" type="main" xml:lang="en">Danger signals and skin sensitization</title>
<author xml:id="author-1">
<persName>
<forename type="first">I.</forename>
<surname>Kimber</surname>
</persName>
<affiliation>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</affiliation>
</author>
<author xml:id="author-2">
<persName>
<forename type="first">M.</forename>
<surname>Cumberbatch</surname>
</persName>
<affiliation>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</affiliation>
</author>
<author xml:id="author-3">
<persName>
<forename type="first">R.J.</forename>
<surname>Dearman</surname>
</persName>
<affiliation>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</affiliation>
</author>
<author xml:id="author-4">
<persName>
<forename type="first">C.E.M.</forename>
<surname>Griffiths</surname>
</persName>
<affiliation>The Dermatology Centre, University of Manchester, Manchester, U.K. Correspondence: I. Kimber E‐mail: ian.kimber@syngenta.com</affiliation>
</author>
</analytic>
<monogr>
<title level="j">British Journal of Dermatology</title>
<idno type="pISSN">0007-0963</idno>
<idno type="eISSN">1365-2133</idno>
<idno type="DOI">10.1111/(ISSN)1365-2133</idno>
<imprint>
<publisher>Blackwell Science Ltd</publisher>
<pubPlace>Oxford, UK</pubPlace>
<date type="published" when="2002-09"></date>
<biblScope unit="volume">147</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="613">613</biblScope>
<biblScope unit="page" to="613">613</biblScope>
</imprint>
</monogr>
<idno type="istex">8D83CB0E5B4E7E46ABB16B639A65C513623A8340</idno>
<idno type="DOI">10.1046/j.1365-2133.2002.48776.x</idno>
<idno type="ArticleID">BJD4877_6</idno>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<creation>
<date>2002</date>
</creation>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
<revisionDesc>
<change when="2002-09">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item>
<extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/8D83CB0E5B4E7E46ABB16B639A65C513623A8340/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata>
<istex:metadataXml wicri:clean="Wiley, elements deleted: body">
<istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document>
<component version="2.0" type="serialArticle" xml:lang="en">
<header>
<publicationMeta level="product">
<publisherInfo>
<publisherName>Blackwell Science Ltd</publisherName>
<publisherLoc>Oxford, UK</publisherLoc>
</publisherInfo>
<doi origin="wiley" registered="yes">10.1111/(ISSN)1365-2133</doi>
<issn type="print">0007-0963</issn>
<issn type="electronic">1365-2133</issn>
<idGroup>
<id type="product" value="BJD"></id>
<id type="publisherDivision" value="ST"></id>
</idGroup>
<titleGroup>
<title type="main" sort="BRITISH JOURNAL OF DERMATOLOGY">British Journal of Dermatology</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="09003">
<doi origin="wiley">10.1111/bjd.2002.147.issue-3</doi>
<numberingGroup>
<numbering type="journalVolume" number="147">147</numbering>
<numbering type="journalIssue" number="3">3</numbering>
</numberingGroup>
<coverDate startDate="2002-09">September 2002</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="letter" position="0061300" status="forIssue">
<doi origin="wiley">10.1046/j.1365-2133.2002.48776.x</doi>
<idGroup>
<id type="unit" value="BJD4877_6"></id>
</idGroup>
<countGroup>
<count type="pageTotal" number="2"></count>
</countGroup>
<titleGroup>
<title type="tocHeading1">Correspondence</title>
</titleGroup>
<eventGroup>
<event type="firstOnline" date="2002-10-04"></event>
<event type="publishedOnlineFinalForm" date="2002-10-04"></event>
<event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.6 mode:FullText source:HeaderRef result:HeaderRef" date="2010-04-29"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-15"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-15"></event>
</eventGroup>
<numberingGroup>
<numbering type="pageFirst" number="613">613</numbering>
<numbering type="pageLast" number="613">613</numbering>
</numberingGroup>
<linkGroup>
<link type="toTypesetVersion" href="file:BJD.BJD4877_6.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta>
<countGroup>
<count type="figureTotal" number="0"></count>
<count type="tableTotal" number="0"></count>
<count type="formulaTotal" number="0"></count>
<count type="referenceTotal" number="13"></count>
<count type="wordTotal" number="1777"></count>
<count type="linksPubMed" number="0"></count>
<count type="linksCrossRef" number="0"></count>
</countGroup>
<titleGroup>
<title type="main">Danger signals and skin sensitization</title>
<title type="shortAuthors">CORRESPONDENCE</title>
<title type="short">CORRESPONDENCE</title>
</titleGroup>
<creators>
<creator creatorRole="author" xml:id="cr1" affiliationRef="#a1-6">
<personName>
<givenNames>I.</givenNames>
<familyName>Kimber</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr2" affiliationRef="#a1-6">
<personName>
<givenNames>M.</givenNames>
<familyName>Cumberbatch</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr3" affiliationRef="#a1-6">
<personName>
<givenNames>R.J.</givenNames>
<familyName>Dearman</familyName>
</personName>
</creator>
<creator creatorRole="author" xml:id="cr4" affiliationRef="#a2-6">
<personName>
<givenNames>C.E.M.</givenNames>
<familyName>Griffiths</familyName>
</personName>
</creator>
</creators>
<affiliationGroup>
<affiliation xml:id="a1-6">
<unparsedAffiliation>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</unparsedAffiliation>
</affiliation>
<affiliation xml:id="a2-6">
<unparsedAffiliation> The Dermatology Centre, University of Manchester, Manchester, U.K. Correspondence: I. Kimber E‐mail:
<email>ian.kimber@syngenta.com</email>
</unparsedAffiliation>
</affiliation>
</affiliationGroup>
</contentMeta>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6">
<titleInfo lang="en">
<title>Danger signals and skin sensitization</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en">
<title>CORRESPONDENCE</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en">
<title>Danger signals and skin sensitization</title>
</titleInfo>
<name type="personal">
<namePart type="given">I.</namePart>
<namePart type="family">Kimber</namePart>
<affiliation>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">M.</namePart>
<namePart type="family">Cumberbatch</namePart>
<affiliation>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">R.J.</namePart>
<namePart type="family">Dearman</namePart>
<affiliation>Syngenta Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, U.K.</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">C.E.M.</namePart>
<namePart type="family">Griffiths</namePart>
<affiliation>The Dermatology Centre, University of Manchester, Manchester, U.K. Correspondence: I. Kimber E‐mail: ian.kimber@syngenta.com</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="review-article" displayLabel="letter"></genre>
<originInfo>
<publisher>Blackwell Science Ltd</publisher>
<place>
<placeTerm type="text">Oxford, UK</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2002-09</dateIssued>
<copyrightDate encoding="w3cdtf">2002</copyrightDate>
</originInfo>
<language>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription>
<internetMediaType>text/html</internetMediaType>
<extent unit="references">13</extent>
<extent unit="words">1777</extent>
</physicalDescription>
<relatedItem type="host">
<titleInfo>
<title>British Journal of Dermatology</title>
</titleInfo>
<genre type="journal">journal</genre>
<identifier type="ISSN">0007-0963</identifier>
<identifier type="eISSN">1365-2133</identifier>
<identifier type="DOI">10.1111/(ISSN)1365-2133</identifier>
<identifier type="PublisherID">BJD</identifier>
<part>
<date>2002</date>
<detail type="volume">
<caption>vol.</caption>
<number>147</number>
</detail>
<detail type="issue">
<caption>no.</caption>
<number>3</number>
</detail>
<extent unit="pages">
<start>613</start>
<end>613</end>
<total>2</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">8D83CB0E5B4E7E46ABB16B639A65C513623A8340</identifier>
<identifier type="DOI">10.1046/j.1365-2133.2002.48776.x</identifier>
<identifier type="ArticleID">BJD4877_6</identifier>
<recordInfo>
<recordContentSource>WILEY</recordContentSource>
<recordOrigin>Blackwell Science Ltd</recordOrigin>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sarre/explor/MusicSarreV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E56 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000E56 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sarre
   |area=    MusicSarreV3
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:8D83CB0E5B4E7E46ABB16B639A65C513623A8340
   |texte=   Danger signals and skin sensitization
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Sun Jul 15 18:16:09 2018. Site generation: Tue Mar 5 19:21:25 2024